Wegovy Linked To Lower Heart Risks Than Similar Drugs, Study Shows
WEDNESDAY, Sept. 3, 2025 — The weight-loss drug Wegovy may lower the risk of heart attack, stroke or death more than similar medications, according to new research from its maker, Novo Nordisk.
In a study of more than 21,000 patients with obesity and heart disease but no diabetes, those taking Wegovy — which contains the active ingredient semaglutide — saw a 57% greater reduction in heart-related risks compared to people taking tirzepatide, the ingredient in Eli Lilly’s weight-loss drugs Mounjaro and Zepbound.
The findings were presented at a medical conference and have not yet been peer-reviewed or published. As such, they should be regarded as preliminary.
“This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes," Ludovic Helfgott, Novo Nordisk’s head of product and portfolio strategy, said in a news release.
The real-world study looked at medical records rather than results from a controlled clinical trial.
Patients taking 2.4 mg of Wegovy had 15 cardiovascular events — about 0.1% of participants — compared with 39 events (0.4%) among those taking tirzepatide when treatment lasted more than 30 days, the study found.
Even when researchers included patients who paused their medications for more than 30 days, Wegovy users still saw a 29% lower risk of heart attack, stroke or death compared with those using tirzepatide.
The results were presented Sunday at the European Society of Cardiology Congress in Madrid.
As of Monday, Eli Lilly had not yet responded to the findings, The Wall Street Journal said.
Sources
- Novo Nordisk, news release, Aug. 31, 2025
- The Wall Street Journal, Sept. 1, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Heart Disease Remains Top Killer Worldwide
THURSDAY, Sept. 25, 2025 — Heart disease remains the world’s top killer, causing 1 in every 3 deaths around the globe, a new study says. Worldwide, the number of...
Wildfire Smoke Now Kills 41,000 Americans a Year, Study Finds
FRIDAY, Sept. 19, 2025 — Every summer, hazy skies and the smell of burning wood remind Americans that wildfires affect far more than just the communities where they...
Can Mammograms Assess Women's Heart Health?
WEDNESDAY, Sept. 17, 2025 — Regular mammograms might offer a “two-for-one” opportunity to protect women’s health, a new study says. Mammograms can be used...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.